Premium Nahrungsergänzungsmittel | artgerecht

Complement-Dependent Cytotoxicity (CDC) Explained

Complement-dependent cytotoxicity (CDC) is an immune mechanism in which antibodies and the complement system work together to destroy target cells. It plays a key role in immune defense and cancer therapy.

Regular tips about health Regular tips about health

Things worth knowing about "Complement-dependent cytotoxicity"

Complement-dependent cytotoxicity (CDC) is an immune mechanism in which antibodies and the complement system work together to destroy target cells. It plays a key role in immune defense and cancer therapy.

What is Complement-Dependent Cytotoxicity?

Complement-dependent cytotoxicity (CDC) is an immunological defense mechanism of the human body. In this process, antibodies bind to target cells – such as pathogens or malignant tumor cells – and subsequently activate the complement system. The complement system is a part of the innate immune system and consists of a series of proteins in the blood that can trigger a cascade of reactions.

The goal of this reaction chain is the destruction of the labeled target cell through the formation of a so-called membrane attack complex (MAC). This complex punctures the cell membrane, leading to cell death. CDC is therefore a central effector mechanism of the humoral immune system.

Mechanism of Action

The process of complement-dependent cytotoxicity can be divided into several steps:

Antibody binding: Antibodies (mainly of the IgG or IgM type) bind via their Fab fragment to specific antigens on the surface of the target cell.
Complement activation: The Fc fragment of the bound antibody activates the first protein of the classical complement cascade, C1q, initiating the classical activation pathway of the complement system.
Complement cascade: Activation of C1q leads to the sequential activation of further complement proteins (C2, C3, C4, C5 through C9). This generates opsonins (e.g., C3b), which attract additional immune cells, as well as anaphylatoxins (e.g., C3a, C5a), which amplify inflammatory responses.
Formation of the membrane attack complex (MAC): At the end of the cascade, proteins C5b, C6, C7, C8, and multiple C9 molecules assemble into the MAC. This complex inserts itself into the cell membrane of the target cell, forming pores through which water and ions flow. The cell swells and undergoes lysis (cell death).

Importance for the Immune System

CDC is a fundamental protective mechanism of the immune system against bacterial infections, viruses, and other foreign substances. Once the immune system has produced specific antibodies against a pathogen – whether through infection or vaccination – CDC can contribute to the rapid elimination of labeled cells.

In some cases, however, CDC can also attack the body's own cells, for example in autoimmune diseases, where antibodies are mistakenly directed against endogenous structures.

Clinical Relevance and Therapeutic Use

CDC plays an important role in modern medicine, particularly in cancer immunotherapy. Therapeutic monoclonal antibodies are specifically designed to label tumor cells and subsequently activate the complement system to destroy them.

Rituximab (for non-Hodgkin lymphoma and other B-cell disorders): This antibody binds to the surface protein CD20 on B cells and triggers their destruction via CDC.
Ofatumumab and Obinutuzumab (for chronic lymphocytic leukemia): Additional anti-CD20 antibodies that utilize CDC as a mechanism of action.
Alemtuzumab (for multiple sclerosis and certain leukemia types): Binds to CD52 on lymphocytes and activates CDC.

The ability of a therapeutic antibody to trigger CDC depends on factors such as its isotype (e.g., IgG1, IgG3), its affinity for the antigen, and the density of the antigen on the target cell surface.

Laboratory Diagnostic Significance

CDC assays are also used in transplant medicine. In the so-called crossmatch test, it is examined whether the blood serum of a recipient contains antibodies directed against the cells of the donor. A positive CDC crossmatch reaction indicates a high risk of rejection and can represent a contraindication for transplantation.

References

Murphy K, Weaver C: Janeway's Immunobiology. 9th edition. Garland Science, New York, 2017.
Nimmerjahn F, Ravetch JV: Antibody-mediated modulation of immune responses. Immunological Reviews, 2010; 236(1): 265–275. PubMed PMID: 20636824.
Weiner LM, Surana R, Wang S: Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nature Reviews Immunology, 2010; 10(5): 317–327. PubMed PMID: 20414205.

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.